The new vaccine, "which has passed all study and test trials, was shown to be 95.5 percent effective in reducing severe cases of the disease, including the hemorrhagic type, during the testing phase in Brazil and Latin America," the official said.

“The vaccine, developed by French pharmaceutical firm Sanofi Pasteur, is the first fully developed dengue vaccine in the world," the official added.

The official said the tested vaccine is safe and will help in bringing down the number of dengue patients needed to be treated in hospitals.

The vaccine needs to be applied three times at an interval of six-months.

Dengue fever is a recurrent problem in Brazil, especially during the rainy summers, when outbreaks occur in different parts of the country.

According to reports, a total of 377 people had died from dengue fever in Brazil till first week of October, and 5,47,600 dengue cases had been reported nationwide.

The situation, however, has improved since last year, when more than a million cases were reported.

The mosquito-borne disease not only affects several countries in Central and South America with tropical climates, but also many countries in Africa and Asia.

The vaccine maker is expected to file for approval by Brazil's National Health Monitoring Agency in early next year, and have the drug commercially available by 2015 end.